Related Experiment Video
Updated: Aug 13, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation
Lunhua Liu1, Yili Xie, Liguang Lou
1Shanghai Institute of Materia Medica, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
Abstract:
The Ras/Raf/extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling pathway is known to cross-talk with other signaling pathways, including phosphatidylinositol 3-kinase (PI3K)/Akt pathway. However, the role of PI3K in ERK-1/2 activation induced by tyrosine kinase receptors was not fully understood. Here, we report that two structurally distinct PI3K inhibitors, wortmannin and LY294002, inhibited insulin-induced activation of ERK1/2 but had no effect on EGF-induced activation of ERK1/2 in hepatocellular carcinoma BEL-7402 and SMMC-7721 cells, breast cancer MCF-7 cells, and prostate cancer LNCaP cells. Although protein kinase C could act as a mediator between PI3K and ERK1/2, protein kinase C inhibitor chelerythrine chloride did not inhibit insulin-induced ERK1/2 activation. Both insulin- and EGF-induced ERK1/2 activation are strictly dependent on Ras activation, however, wortmannin only inhibited insulin-induced, but not EGF-induced Ras activation. These results indicate that PI3K plays different roles in the activation of Ras/ERK1/2 signaling by insulin and EGF, and that insulin-stimulated, but not EGF-stimulated, ERK1/2 and Akt signalings diverge at PI3K.
Insights
Phosphatidylinositol 3-kinase (PI3K) differentially regulates insulin and EGF signaling pathways. PI3K is crucial for insulin-induced Ras/ERK1/2 activation but not EGF-induced activation, indicating pathway divergence.
Area of Science:
- Cellular signaling pathways
- Molecular biology
- Cancer research
Background:
- The Ras/Raf/extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathway interacts with other signaling cascades, such as phosphatidylinositol 3-kinase (PI3K)/Akt.
- The precise role of PI3K in tyrosine kinase receptor-mediated ERK1/2 activation remains unclear.
Purpose of the Study:
- To investigate the role of PI3K in insulin- and EGF-induced ERK1/2 activation in various cancer cell lines.
- To elucidate the specific mechanisms by which PI3K influences Ras/ERK1/2 signaling in response to different stimuli.
Main Methods:
- Utilized PI3K inhibitors (wortmannin, LY294002) and a protein kinase C inhibitor (chelerythrine chloride).
- Assessed the activation of ERK1/2 and Ras in response to insulin and EGF stimulation in hepatocellular carcinoma (BEL-7402, SMMC-7721), breast cancer (MCF-7), and prostate cancer (LNCaP) cells.
- Analyzed the divergence point of insulin-stimulated ERK1/2 and Akt signaling.
Main Results:
- PI3K inhibitors blocked insulin-induced ERK1/2 activation but not EGF-induced activation in all tested cancer cell lines.
- Protein kinase C inhibition did not affect insulin-induced ERK1/2 activation.
- While both insulin and EGF require Ras activation for ERK1/2 activation, wortmannin selectively inhibited insulin-induced Ras activation.
- Insulin-stimulated ERK1/2 and Akt signaling pathways diverge at the PI3K level.
Conclusions:
- PI3K plays a distinct role in mediating insulin-induced Ras/ERK1/2 activation compared to EGF-induced activation.
- The findings highlight differential regulation of signaling pathways by insulin and EGF, with implications for targeted cancer therapies.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Insulin: The Receptor and Signaling Pathways
cAMP-dependent Protein Kinase Pathways
MAPK Signaling Cascades
IP3/DAG Signaling Pathway
The JAK-STAT Signaling Pathway
